title: Overall survival should be the primary endpoint in clinical trials for advanced non-small-cell lung cancer.
abstract: An article in a recent edition of Current Oncology explored the validation of progression-free survival (pfs) as an endpoint in clinical trials of antineoplastic agents for metastatic colorectal cancer, metastatic renal cell carcinoma, and ovarian cancer. The support for pfs as a surrogate endpoint for overall survival (os) was elucidated. As with the aforementioned tumour types, advanced non-small-cell lung cancer (nsclc) has seen a rise in active agents since the year 2000. Those agents range from improved cytotoxics such as pemetrexed, to targeted therapies such as tyrosine kinase inhibitors of the epidermal growth factor receptor and agents that target the EML4-ALK gene mutation. More recently, it has also become apparent that histology plays an important role in the response to and outcomes of treatment. With the therapeutic options for patients with advanced nsclc increasing, concerns are being raised that the efficacy of drugs measured by os may be diluted in clinical trials, thereby underestimating their true clinical benefit. That possibility, together with the need to have efficacious drugs available to patients earlier, has resulted in the search for a surrogate to the os endpoint in advanced nsclc. The present article follows up the recent article on pfs as a surrogate. Although advances in identifying pfs as a valid surrogate endpoint for os have been made in other tumour types, in advanced nsclc, such surrogacy has not been formally validated. Until it has, os should remain the primary endpoint of clinical trials in advanced nsclc.
authors.affiliation: Sunnybrook Health Sciences Centre/Odette Cancer Centre, Toronto, ON.
authors.forename: P K
authors.initials: PK
authors.lastname: Cheema
authors.forename: R L
authors.initials: RL
authors.lastname: Burkes
keywords: Progression-free survival; endpoint; non-small-cell lung cancer; overall survival
references.citation: Stat Med. 1989 Apr;8(4):431-40
references.pmid: 2727467
references.citation: Curr Control Trials Cardiovasc Med. 2002 Jan 8;3(1):4
references.pmid: 11985778
references.citation: Int J Technol Assess Health Care. 2008 Fall;24(4):371-83
references.pmid: 18828930
references.citation: J Natl Cancer Inst. 2010 Feb 24;102(4):230-43
references.pmid: 20118413
references.citation: Ann Oncol. 2012 Jun;23(6):1646-51
references.pmid: 22048151
references.citation: N Engl J Med. 2002 Jan 10;346(2):92-8
references.pmid: 11784875
references.citation: J Clin Oncol. 2014 May 10;32(14):1407-11
references.pmid: 24590634
references.citation: J Clin Oncol. 1993 May;11(5):873-8
references.pmid: 8387576
references.citation: Transl Lung Cancer Res. 2012 Mar;1(1):26-35
references.pmid: 25806152
references.citation: J Clin Oncol. 2008 Jul 20;26(21):3543-51
references.pmid: 18506025
references.citation: J Clin Oncol. 2012 Apr 1;30(10):1114-21
references.pmid: 22370318
references.citation: Lancet Oncol. 2010 Jun;11(6):521-9
references.pmid: 20493771
references.citation: J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
references.pmid: 10655437
references.citation: Lancet. 2009 Oct 24;374(9699):1432-40
references.pmid: 19767093
references.citation: Lancet Oncol. 2012 Mar;13(3):247-55
references.pmid: 22341744
references.citation: Stat Methods Med Res. 2008 Oct;17(5):467-75
references.pmid: 18285439
references.citation: Lancet. 2009 May 2;373(9674):1525-31
references.pmid: 19410716
references.citation: N Engl J Med. 2009 Sep 3;361(10):947-57
references.pmid: 19692680
references.citation: J Clin Oncol. 2012 Apr 1;30(10):1122-8
references.pmid: 22370314
references.citation: N Engl J Med. 2005 Jul 14;353(2):123-32
references.pmid: 16014882
references.citation: J Clin Oncol. 2008 Jan 20;26(3):463-7
references.pmid: 18202421
references.citation: Eur J Cancer. 2002 Sep;38(14):1817-23
references.pmid: 12204662
references.citation: Clin Cancer Res. 2011 Oct 1;17(19):6298-303
references.pmid: 21856766
references.citation: J Clin Oncol. 2009 Jul 10;27(20):3277-83
references.pmid: 19470938
references.citation: N Engl J Med. 2006 Dec 14;355(24):2542-50
references.pmid: 17167137
references.citation: J Thorac Oncol. 2010 Sep;5(9):1416-23
references.pmid: 20686429
references.citation: CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29
references.pmid: 14974761
references.citation: J Natl Cancer Inst. 2009 Dec 2;101(23):1642-9
references.pmid: 19903805
references.citation: Curr Oncol. 2011 Oct;18 Suppl 2:S3-4
references.pmid: 21969809
references.citation: Ann Oncol. 2010 Sep;21(9):1804-1809
references.pmid: 20150572
references.citation: Br J Cancer. 2008 Nov 18;99(10):1572-8
references.pmid: 19002178
references.citation: Lancet Oncol. 2011 Aug;12(8):735-42
references.pmid: 21783417
references.citation: J Thorac Oncol. 2007 Oct;2(10):939-46
references.pmid: 17909357
references.citation: J Clin Oncol. 2000 Oct 1;18(19):3390-9
references.pmid: 11013280
references.citation: Lancet Oncol. 2010 Feb;11(2):121-8
references.pmid: 20022809
references.citation: J Clin Oncol. 2012 Apr 1;30(10):1030-3
references.pmid: 22370321
references.citation: J Clin Oncol. 1988 Apr;6(4):633-41
references.pmid: 2833577
references.citation: Lancet Oncol. 2012 May;13(5):528-38
references.pmid: 22452896
references.citation: N Engl J Med. 2010 Aug 19;363(8):733-42
references.pmid: 20818875
references.citation: J Clin Oncol. 2009 Mar 10;27(8):1227-34
references.pmid: 19188680
references.citation: J Thorac Oncol. 2010 Jan;5(1):3-9
references.pmid: 19884856
references.citation: J Clin Oncol. 2000 Jun;18(12):2354-62
references.pmid: 10856094
references.citation: J Clin Oncol. 2000 May;18(10):2095-103
references.pmid: 10811675
references.citation: Lancet. 2005 Oct 29-Nov 4;366(9496):1527-37
references.pmid: 16257339
references.citation: J Clin Oncol. 2009 Feb 1;27(4):591-8
references.pmid: 19075278
references.citation: Lancet Oncol. 2012 Mar;13(3):239-46
references.pmid: 22285168
references.citation: J Clin Oncol. 2004 May 1;22(9):1589-97
references.pmid: 15117980
references.citation: J Clin Oncol. 2011 Jul 20;29(21):2866-74
references.pmid: 21670455